DARE / Daré Bioscience, Inc. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 2, 2025 DARE BIOSCIENCE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 2, 2025 DARE BIOSCIENCE, INC. DARÉ BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36395 20-4139823 (State or other jurisdiction of inco

EX-99.1

Exhibit 99.1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2025 DARÉ BIOSCIENCE,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2025 DARÉ BIOSCIENCE, INC. DARE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36395 20-4139823 (State or other jurisdiction of incorp

Filing Fee Table

Exhibit 107.1 Calculation of Filing Fee Table Form S-8 (Form Type) Daré Bioscience, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security type Security class title Fee calculation rule Amount registered (1) Proposed maximum offering price per unit (2) Maximum aggregate offering price Fee rate Amount of registration fee Equity Common stock, $0.000

Daré Bioscience, Inc. and Subsidiaries Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)

Exhibit 99.1 Daré Bioscience Reports Second Quarter 2025 Financial Results and Provides Corporate Update DARE to PLAY™ Sildenafil Cream on Track for Q4 2025 Launch via 503B Compounding Pathway; Positioned for Product Revenue Beginning in Q4 2025 Positive Interim DSMB Outcome for Ovaprene® Phase 3 Study Supports Continued Enrollment Multiple Grant-Funded Programs Advance, Including to Address HPV a

As filed with the Securities and Exchange Commission on August 14, 2025

As filed with the Securities and Exchange Commission on August 14, 2025 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36395 DARÉ BIOSCIENCE, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 25, 2025 DARE BIOSCIENCE, IN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 25, 2025 DARE BIOSCIENCE, INC. DARÉ BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36395 20-4139823 (State or other jurisdiction of incorpor

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 18, 2025 Dare Bioscience, In

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 18, 2025 Dare Bioscience, Inc. DARÉ BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36395 20-4139823 (State or other jurisdiction of incorpor

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 14, 2025 Dare Bioscience, In

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 14, 2025 Dare Bioscience, Inc. DARÉ BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36395 20-4139823 (State or other jurisdiction of incorpor

Positive Interim Phase 3 Results Highlight Potential of Ovaprene

Exhibit 99.1 Positive Interim Phase 3 Results Highlight Potential of Ovaprene®, Novel Hormone-Free Contraceptive Interim Phase 3 Results Support Ovaprene’s Differentiation as a First-in-Category, Hormone-Free, Intravaginal Monthly Contraceptive SAN DIEGO, July 14, 2025 (GLOBE NEWSWIRE) — Daré Bioscience, Inc. (NASDAQ: DARE), a biopharmaceutical company driven by a mission to challenge the status q

Submission of Matters to a Vote of Security Holders, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 9, 2025 Dare Bioscience, Inc. DARÉ BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36395 20-4139823 (State or other jurisdiction of incorpora

Amendment No. 1 to Daré Bioscience, Inc. 2022 Stock Incentive Plan

Exhibit 10.1 Amendment No. 1 to Daré Bioscience, Inc. 2022 Stock Incentive Plan This Amendment No. 1 (this “Amendment”) to the Daré Bioscience, Inc. 2022 Stock Incentive Plan (the “Plan”) is adopted by Daré Bioscience, Inc. (the “Company”), effective as of July 9, 2025, the date it was approved by the Company’s stockholders. Capitalized terms used but not otherwise defined herein shall have the me

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2025 Dare Bioscience, In

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2025 Dare Bioscience, Inc. DARÉ BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36395 20-4139823 (State or other jurisdiction of incorpor

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2025 Dare Bioscience, Inc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2025 Dare Bioscience, Inc. DARÉ BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36395 20-4139823 (State or other jurisdiction of incorpora

Daré Bioscience corporate presentation, dated June 9, 2025

Exhibit 99.1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36395 DARÉ BIOSCIENCE, INC.

Daré Bioscience Reports First Quarter 2025 Financial Results and Provides Company Update In addition to its proprietary Sildenafil Cream formulation, Daré is taking action to make three other solutions for women available commercially, two vaginal pr

Exhibit 99.1 Daré Bioscience Reports First Quarter 2025 Financial Results and Provides Company Update In addition to its proprietary Sildenafil Cream formulation, Daré is taking action to make three other solutions for women available commercially, two vaginal probiotics in 2025 and its proprietary monthly hormone therapy in 2026 ● Creates commercial opportunity in the estimated up to $4.5 billion

Results of Operations and Financial Condition, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2025 DARÉ BIOSCIENCE, INC. Dare Bioscience, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36395 20-4139823 (State or other jurisdiction of incorpora

mended and Restated Non-Employee Director Compensation Policy (as amended

Exhibit 10.1 DARÉ BIOSCIENCE, INC. AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY1 The board of directors (the “Board”) of Daré Bioscience, Inc. (the “Company”) has approved this amended and restated non-employee director compensation policy (this “Policy”). Cash Compensation Under this Policy, the Company will pay its non-employee directors retainers in cash, unless a director ele

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________________________ FORM 10-K ___________________________________________________ ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File No. 001-36395 DARÉ BIOSCIENCE, INC. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 11, 2025 DARÉ BIOSCIENCE, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 11, 2025 DARÉ BIOSCIENCE, INC. DARE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36395 20-4139823 (State or other jurisdiction of incorpo

Subsidiaries of the registrant

Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT Name Jurisdiction of Organization Daré Bioscience Operations, Inc. Delaware Daré Bioscience Australia Pty Ltd Australia Pear Tree Pharmaceuticals, Inc. Delaware Daré MBI Inc. Delaware

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File No. 001-36395 DARÉ BIOSCIENCE, INC. (Exact

Daré Bioscience Reports Full Year 2024 Financial Results and Provides Company Update With increasing demand for needed treatments designed for women, Daré is taking action to make its proprietary Sildenafil Cream formulation available via prescriptio

Exhibit 99.1 Daré Bioscience Reports Full Year 2024 Financial Results and Provides Company Update With increasing demand for needed treatments designed for women, Daré is taking action to make its proprietary Sildenafil Cream formulation available via prescription this year ● Enables women to access a solution that they want and need ● Creates an opportunity to accelerate revenue generation from t

Results of Operations and Financial Condition, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2025 DARÉ BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36395 20-4139823 (State or other jurisdiction of incorporation) (Commission Fi

Daré Bioscience, Inc.

DARÉ BIOSCIENCE, INC. AMENDED AND RESTATED INSIDER TRADING POLICY (effective October 22, 2024) TABLE OF CONTENTS Page I. The Need for an Insider Trading Policy............................................................. 2 II. What is Material Non-Public Information? ........................................................ 2 III. The Consequences of Insider Trading ................................

the Consortium Management Firm, National Collegiate Inventor

1 Subaward Agreement No. SWH-08 Exhibit 10.13 CERTAIN INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. IN THIS EXHIBIT, “[***]” INDICATES WHERE SUCH INFORMATION HAS BEEN OMITTED. SUBAWARD AGREEMENT This Subaward Agreement (this “Agreement”) is entered into on October 23, 2024 (the “Effective Date”

Grant Agreement between Daré Bioscience, Inc. and the Bill & Melinda Gates Foundation effective as of June 30, 2021

1 of 9 Exhibit 10.11 CERTAIN INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. IN THIS EXHIBIT, “[***]” INDICATES WHERE SUCH INFORMATION HAS BEEN OMITTED. GRANT AGREEMENT Investment ID INV-026060 AGREEMENT SUMMARY & SIGNATURE PAGE GRANTEE INFORMATION Name: Dare Bioscience, Inc. Tax Status: Not exem

etween Douglas Pharmaceuticals

Exhibit 10.10 CERTAIN INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. IN THIS EXHIBIT, “[***]” INDICATES WHERE SUCH INFORMATION HAS BEEN OMITTED. EXCLUSIVE LICENSE AGREEMENT This Exclusive License Agreement (this “Agreement”) is made as August 12, 2023 (“Effective Date”), by and between Douglas P

Grant Agreement between Daré Bioscience, Inc. and the Bill & Melinda Gates Foundation effective as of

1 of 9 Exhibit 10.12 CERTAIN INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. IN THIS EXHIBIT, “[***]” INDICATES WHERE SUCH INFORMATION HAS BEEN OMITTED. GRANT AGREEMENT Investment ID INV-074353 AGREEMENT SUMMARY & SIGNATURE PAGE GRANTEE INFORMATION Name: Dare Bioscience, Inc. Tax Status: Not exem

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2025 DARÉ BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36395 20-4139823 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 10, 2025 DARÉ BIOSCIENCE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 10, 2025 DARÉ BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36395 20-4139823 (State or other jurisdiction of incorporation) (Commission

Daré Bioscience corporate presentation, dated February 10, 2025

Exhibit 99.1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 DARÉ BIOSCIENCE,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 DARÉ BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36395 20-4139823 (State or other jurisdiction of incorporation) (Commission

Daré Bioscience corporate presentation, dated January 13, 2025

Exhibit 99.1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2024 DARÉ BIOSCIENCE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2024 DARÉ BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36395 20-4139823 (State or other jurisdiction of incorporation) (Commission

Daré Bioscience Announces Phase 3 Plans for Sildenafil Cream, 3.6%, in the Treatment of Female Sexual Arousal Disorder (FSAD) FSAD is clinically analogous to erectile dysfunction in men. To date, there are no FDA-approved pharmacological treatments f

Exhibit 99.1 Daré Bioscience Announces Phase 3 Plans for Sildenafil Cream, 3.6%, in the Treatment of Female Sexual Arousal Disorder (FSAD) FSAD is clinically analogous to erectile dysfunction in men. To date, there are no FDA-approved pharmacological treatments for FSAD; Daré’s Sildenafil Cream has the potential to receive the first FDA approval for FSAD. Market research estimates approximately 10

Daré Bioscience, Inc. 2,750,000 Shares of Common Stock

Filed Pursuant to Rule 424(b)(3) Registration No. 333-283280 PROSPECTUS Daré Bioscience, Inc. 2,750,000 Shares of Common Stock This prospectus relates to the resale, from time to time, of up to 2,750,000 shares of our common stock, par value $0.0001, by Lincoln Park Capital Fund, LLC, or Lincoln Park or the selling stockholder. The shares of common stock to which this prospectus relates are shares

Daré Bioscience, Inc. 3655 Nobel Drive, Suite 260 San Diego, CA 92122

Daré Bioscience, Inc. 3655 Nobel Drive, Suite 260 San Diego, CA 92122 November 22, 2024 VIA EDGAR United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Tim Buchmiller Re: Daré Bioscience, Inc. Registration Statement on Form S-1 Filed November 15, 2024 File No. 333-283280 Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations

As filed with the Securities and Exchange Commission on November 15, 2024

As filed with the Securities and Exchange Commission on November 15, 2024 Registration No.

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Table FORM S-1 (Form Type) DARÉ BIOSCIENCE, INC.

Daré Bioscience, Inc. and Subsidiaries Condensed Consolidated Statements of Operations and Comprehensive Loss

Exhibit 99.1 Daré Bioscience Reports Third Quarter 2024 Financial Results and Provides Company Update Conference Call and Webcast Today at 4:30 p.m. ET Development Program Highlights and Anticipated Milestones ● Ovaprene® hormone-free monthly intravaginal contraceptive candidate – pivotal Phase 3 contraceptive efficacy study recruiting across the United States; foundation grant announced yesterday

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36395 DARÉ BIOSCIENCE, INC.

Results of Operations and Financial Condition, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2024 DARÉ BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36395 20-4139823 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 25, 2024 DARÉ BIOSCIENCE,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 25, 2024 DARÉ BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36395 20-4139823 (State or other jurisdiction of incorporation) (Commission

Daré Bioscience corporate presentation, dated October 25, 2024

Exhibit 99.1

Daré Bioscience Selected to Receive $10 Million Award from ARPA-H’s Sprint for Women’s Health DARE-HPV is a potential first-in-category treatment for human papillomavirus (HPV)-related cervical disease which could change the treatment paradigm for cl

Exhibit 99.1 Daré Bioscience Selected to Receive $10 Million Award from ARPA-H’s Sprint for Women’s Health DARE-HPV is a potential first-in-category treatment for human papillomavirus (HPV)-related cervical disease which could change the treatment paradigm for clinical HPV management. Essentially all cervical cancer cases worldwide are caused by HPV infection. SAN DIEGO, October 23, 2024 (GLOBE NE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 23, 2024 DARÉ BIOSCIENCE,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 23, 2024 DARÉ BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36395 20-4139823 (State or other jurisdiction of incorporation) (Commission

Registration Rights Agreement, dated October 21, 2024, by and between Daré Bioscience, Inc. and Lincoln Park Capital Fund, LLC

Exhibit 10.2 Execution Version REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of October 21, 2024, is made by and between DARÉ BIOSCIENCE, INC., a Delaware corporation (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (together with its permitted assigns, the “Buyer”). Capitalized terms used herein and not othe

Daré Bioscience Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital Fund, LLC Provides Daré access to capital at Daré’s discretion with any proceeds available to help fund portfolio advancement, such as the Phase

Exhibit 99.1 Daré Bioscience Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital Fund, LLC Provides Daré access to capital at Daré’s discretion with any proceeds available to help fund portfolio advancement, such as the Phase 3 program for Sildenafil Cream, 3.6%, a potential first-in-category treatment for female sexual arousal disorder using the same active i

Purchase Agreement, dated October 21, 2024, by and between Daré Bioscience, Inc. and Lincoln Park Capital Fund, LLC

Exhibit 10.1 Execution Version PURCHASE AGREEMENT THIS PURCHASE AGREEMENT (this “Agreement”), dated as of October 21, 2024, is made by and between DARÉ BIOSCIENCE, INC., a Delaware corporation (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (the “Investor”). WHEREAS: Subject to the terms and conditions set forth in this Agreement, the Company wishes to se

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 21, 2024 DARÉ BIOSCIENCE,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 21, 2024 DARÉ BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36395 20-4139823 (State or other jurisdiction of incorporation) (Commission

* * *

September 10, 2024 Via EDGAR Division of Corporation Finance Office of Life Sciences Attn: Vanessa Robertson and Kevin Vaughn U.

Daré Bioscience, Inc. 2022 Stock Incentive Plan

Exhibit 10.7 DARÉ BIOSCIENCE, INC. 2022 STOCK INCENTIVE PLAN1 Adopted by the Board of Directors: April 11, 2022 Approved by the Shareholders: June 23, 2022 1. Purpose The purpose of this 2022 Stock Incentive Plan (the “Plan”) of Daré Bioscience, Inc., a Delaware corporation (the “Company”), is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract, ret

Traditional Royalty Purchase Agreement between Daré Bioscience, Inc. and XOMA (US) LLC, dated as of April 29, 2024

Exhibit 10.1 CERTAIN INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. IN THIS EXHIBIT, “[***]” INDICATES WHERE SUCH INFORMATION HAS BEEN OMITTED. TRADITIONAL ROYALTY PURCHASE AGREEMENT BY AND BETWEEN DARÉ BIOSCIENCE, INC., AS THE SELLER, AND AND XOMA (US) LLC, AS THE BUYER DATED AS OF APRIL 29, 20

Daré Bioscience, Inc. Change in Control Policy (as amended on April 29, 2024)

Exhibit 10.6 DARÉ BIOSCIENCE, INC. CHANGE IN CONTROL POLICY1 The purpose of this Change in Control Policy (this “Policy”) of Daré Bioscience, Inc. (together with its successors and assigns, the “Company”) is to provide certain employees of the Company with certain benefits in the event of a termination of employment without Cause (as defined below) or for Good Reason (as defined below), in each ca

Results of Operations and Financial Condition, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2024 DARÉ BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36395 20-4139823 (State or other jurisdiction of incorporation) (Commission F

Daré Bioscience, Inc. and Subsidiaries Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)

Exhibit 99.1 Daré Bioscience Reports Second Quarter 2024 Financial Results and Provides Company Update Conference Call and Webcast Today at 4:30 p.m. ET Development Program Highlights and Anticipated 2024 Milestones ● Ovaprene® hormone-free monthly intravaginal contraceptive candidate pivotal Phase 3 contraceptive efficacy study recruiting across the United States ● Sildenafil Cream, 3.6% topical

Amended and Restated Non-Employee Director Compensation Policy (as amended on April 2024)

Exhibit 10.4 DARÉ BIOSCIENCE, INC. AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY1 The board of directors (the “Board”) of Daré Bioscience, Inc. (the “Company”) has approved this amended and restated non-employee director compensation policy (this “Policy”). Cash Compensation Under this Policy, the Company will pay its non-employee directors retainers in cash, unless a director ele

Restated Certificate of Incorporation, as amended to date

Exhibit 3.1 State of Delaware Secretary of State Division of Corporations Delivered 02:52 PM 06/26/2024 FILED 04:01 PM 06/26/24 SR 20242993788 – File Number 4067151 CERTIFICATE OF AMENDMENT OF RESTATED CERTIFICATE OF INCORPORATION OF DARÉ BIOSCIENCE, INC. Daré Bioscience, Inc. (the “Corporation”), a corporation organized and existing under the General Corporation Law of the State of Delaware (the

Amendment No. 3 to Grant Agreement between Daré Bioscience, Inc. and the Bill & Melinda Gates Foundation, dated as of April 18, 2024

Exhibit 10.3 CERTAIN INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. IN THIS EXHIBIT, [**] INDICATES WHERE SUCH INFORMATION HAS BEEN OMITTED. AMENDMENT 3 to GRANT AGREEMENT Investment ID INV-026060 AMENDMENT SUMMARY PAGE AMENDMENT INFORMATION Agreement to be Amended: Grant agreement between the B

Synthetic Royalty Purchase Agreement between Daré Bioscience, Inc. and XOMA (US) LLC, dated as of April 29, 2024

Exhibit 10.2 CERTAIN INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. IN THIS EXHIBIT, “[***]” INDICATES WHERE SUCH INFORMATION HAS BEEN OMITTED. SYNTHETIC ROYALTY PURCHASE AGREEMENT BY AND BETWEEN DARÉ BIOSCIENCE, INC., AS THE SELLER, AND AND XOMA (US) LLC, AS THE BUYER DATED AS OF APRIL 29, 2024

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36395 DARÉ BIOSCIENCE, INC.

Amendment No. 2 to Employment Agreement between Daré Bioscience, Inc. and Sabrina Martucci Johnson, dated as of May 20, 2024

Exhibit 10.5 AMENDMENT NO. 2 TO EMPLOYMENT AGREEMENT This Amendment No. 2 to Employment Agreement (this “Amendment”) is entered into as of May 20, 2024, between Daré Bioscience, Inc. (the “Company”), and the undersigned individual who is an executive of the Company (“Executive”). WHEREAS, the Company and Executive are parties to that certain employment agreement made as of August 15, 2017, as amen

Daré Bioscience Regains Compliance with Nasdaq Minimum Bid Price Rule

Exhibit 99.1 Daré Bioscience Regains Compliance with Nasdaq Minimum Bid Price Rule SAN DIEGO, July 19, 2024 (GLOBE NEWSWIRE) — Daré Bioscience, Inc. (NASDAQ: DARE), a leader in innovation for the health and wellbeing of women, announced that it was notified by the Nasdaq Office of General Counsel that the Company regained compliance with the minimum bid price requirement in Nasdaq Listing Rule 55

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 18, 2024 DARÉ BIOSCIENCE, IN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 18, 2024 DARÉ BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36395 20-4139823 (State or other jurisdiction of incorporation) (Commission Fil

Certificate of Correction of the Certificate of Amendment of Restated Certificate of Incorporation dated June 21, 2024

Exhibit 3.2 CERTIFICATE OF CORRECTION OF THE CERTIFICATE OF AMENDMENT OF RESTATED CERTIFICATE OF INCORPORATION OF DARÉ BIOSCIENCE, INC. Pursuant to the provisions of §103(f) of the General Corporation Law of the State of Delaware Daré Bioscience, Inc. (the “Corporation”), a corporation organized and existing under the General Corporation Law of the State of Delaware (the “DGCL”), hereby certifies

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2024 DARÉ BIOSCIENCE, IN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2024 DARÉ BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36395 20-4139823 (State or other jurisdiction of incorporation) (Commission Fil

Daré Bioscience Announces Reverse Stock Split

Exhibit 99.1 Daré Bioscience Announces Reverse Stock Split Shares Expected to Begin Trading on Split-Adjusted Basis on July 1, 2024 SAN DIEGO, June 27, 2024 (GLOBE NEWSWIRE) - Daré Bioscience, Inc. (NASDAQ: DARE), a leader in innovation for the health and wellbeing of women, today announced that it will implement a 1-for-12 reverse split of the issued shares of its common stock, effective at 12:01

Certificate of Amendment of Restated Certificate of Incorporation dated June 26, 2024

Exhibit 3.1 CERTIFICATE OF AMENDMENT OF RESTATED CERTIFICATE OF INCORPORATION OF DARÉ BIOSCIENCE, INC. Daré Bioscience, Inc. (the “Corporation”), a corporation organized and existing under the General Corporation Law of the State of Delaware (the “DGCL”), hereby certifies as follows: 1. This Certificate of Amendment (this “Certificate of Amendment”) amends the provisions of the Corporation’s Resta

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2024 DARÉ BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36395 20-4139823 (State or other jurisdiction of incorporation) (Commission File

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2024 DARÉ BIOSCIENCE, INC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2024 DARÉ BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36395 20-4139823 (State or other jurisdiction of incorporation) (Commission File

Third Amended and Restated By-laws

SMRH:4856-2097-7468.7 THIRD AMENDED AND RESTATED BY-LAWS OF DARÉ BIOSCIENCE, INC. (as amended through January 24, 2023) Exhibit 3.1 SMRH:4856-2097-7468.7 -i- TABLE OF CONTENTS ARTICLE I STOCKHOLDERS .............................................................................................................. 1 1.1 Place of Meetings ..................................................................

Consulting Agreement by and between Daré Bioscience, Inc. and Lisa Walters-Hoffert, dated as of January 26, 2024

Exhibit 10.1 CONSULTING SERVICES AGREEMENT This Consulting Services Agreement (“Agreement”) is entered into and effective as of January 26, 2024 (“Effective Date”) by and between Daré Bioscience, Inc. (“Company”), and Lisa Walters-Hoffert (“Consultant”). WHEREAS, prior to the Effective Date, Consultant was employed by the Company pursuant to an Employment Agreement dated August 15, 2017, between t

Daré Bioscience, Inc. and Subsidiaries Consolidated Statements of Operations and Comprehensive Loss

Exhibit 99.1 Daré Bioscience Reports First Quarter 2024 Financial Results and Provides Company Update Conference Call and Webcast Today at 4:30 p.m. ET Development Program Highlights and Anticipated 2024 Milestones ● Ovaprene® hormone-free monthly intravaginal contraceptive candidate pivotal Phase 3 contraceptive efficacy study recruiting across the United States ● Sildenafil Cream, 3.6% topical f

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36395 DARÉ BIOSCIENCE, INC.

DARÉ BIOSCIENCE, INC. Up to $18,089,630 Common Stock

Filed Pursuant to Rule 424(b)(5) Registration No. 333-278380 PROSPECTUS SUPPLEMENT (To Prospectus dated May 10, 2024) DARÉ BIOSCIENCE, INC. Up to $18,089,630 Common Stock On March 31, 2023, we entered into a sales agreement, or the Sales Agreement, with Stifel, Nicolaus & Company, Incorporated, or Stifel, and Cantor Fitzgerald & Co., or Cantor, relating to the issuance and sale of shares of our co

Daré Bioscience, Inc. 3655 Nobel Drive, Suite 260 San Diego, California 92122

Daré Bioscience, Inc. 3655 Nobel Drive, Suite 260 San Diego, California 92122 May 8, 2024 Via EDGAR U.S. Securities and Exchange Commission Division of Corporate Finance 100 F Street, NE Washington, DC 20549 Attn: Daniel Crawford Re: Daré Bioscience, Inc. Registration Statement on Form S-3 (File No. 333-278380) Acceleration Request Ladies and Gentlemen: Pursuant to Rule 461 of the Securities Act o

DARÉ BIOSCIENCE, INC. Up to 15,000,000 Shares of Common Stock for Resale Offered by the Selling Stockholders

Filed Pursuant to Rule 424(b)(3) Registration No. 333-278378 PROSPECTUS DARÉ BIOSCIENCE, INC. Up to 15,000,000 Shares of Common Stock for Resale Offered by the Selling Stockholders This prospectus covers the possible offer and resale by the selling stockholders identified in this prospectus of up to an aggregate of 15,000,000 shares of our common stock, all which consist shares of our common stock

Daré Bioscience Secures $22 Million in Non-Dilutive Strategic Royalty Financing to Advance Phase 3 First-in-Category Women’s Health Product Candidates through Key Catalysts

Exhibit 99.1 Daré Bioscience Secures $22 Million in Non-Dilutive Strategic Royalty Financing to Advance Phase 3 First-in-Category Women’s Health Product Candidates through Key Catalysts $22 million of non-dilutive capital at close provides significant capital to achieve objectives Upon achieving a pre-specified return threshold, XOMA will make upside-sharing milestone payments to Daré representin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2024 DARÉ BIOSCIENCE, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2024 DARÉ BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36395 20-4139823 (State or other jurisdiction of incorporation) (Commission Fi

Daré Bioscience, Inc. 3655 Nobel Drive, Suite 260 San Diego, CA 92122

Daré Bioscience, Inc. 3655 Nobel Drive, Suite 260 San Diego, CA 92122 April 29, 2024 VIA EDGAR United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Daniel Crawford Re: Daré Bioscience, Inc. Registration Statement on Form S-3 Filed March 29, 2024 File No. 333-278378 Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations under

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Daré Bioscience, Inc.

iling Fee Table

Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Daré Bioscience, Inc.

As filed with the Securities and Exchange Commission on March 29, 2024

As filed with the Securities and Exchange Commission on March 29, 2024 Registration No.

Form of Subordinated Indenture

Exhibit 4.11 DARÉ BIOSCIENCE, INC. Issuer AND [ ] Trustee INDENTURE Dated as of [ ] Subordinated Debt Securities CROSS-REFERENCE TABLE (1) Section of Trust Indenture Act of 1939, as Amended Section of Indenture 310(a). 7.09 310(b). 7.08 7.10 310(c). Inapplicable 311(a). 7.13(a) 311(b). 7.13(b) 311(c). Inapplicable 312(a). 5.02(a) 312(b). 5.02(b) 312(c). 5.02(c) 313(a). 5.04(a) 313(b). 5.04(a) 313(

Form of Senior Indenture

Exhibit 4.10 DARÉ BIOSCIENCE, INC. Issuer AND [ ] Trustee INDENTURE Dated as of [ ] Senior Debt Securities 80673602v.2 CROSS-REFERENCE TABLE (1) Section of Trust Indenture Act Section of of 1939, as Amended Indenture 310(a). 7.09 310(b). 7.08 7.10 310(c). Inapplicable 311(a). 7.13(a) 311(b). 7.13(b) 311(c). Inapplicable 312(a) 5.02(a) 312(b). 5.02(b) 312(c). 5.02(c) 313(a). 5.04(a) 313(b). 5.04(a)

As filed with the Securities and Exchange Commission on March 29, 2024

As filed with the Securities and Exchange Commission on March 29, 2024 Registration No.

Form of common stock purchase warrants issued on December 21, 2023

EXHIBIT 4.4 Form of Warrant DARÉ BIOSCIENCE, INC. Warrant To Purchase Common Stock Warrant No.: [ ] Date of Issuance: [ ] (“Issuance Date”) THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after [ ]1 (

Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company Update

Exhibit 99.1 Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company Update Conference Call and Webcast Today at 4:30 p.m. ET 2023 Highlights and Anticipated 2024 Milestones ● XACIATO™ (clindamycin phosphate) vaginal gel 2% is available by prescription in the United States to treat bacterial vaginosis under license agreement with commercial collaborator Organon ● Ovaprene® ho

Subsidiaries of the registrant

Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT Name Jurisdiction of Organization Daré Bioscience Operations, Inc. Delaware Daré Bioscience Australia Pty Ltd Australia Pear Tree Pharmaceuticals, Inc. Delaware Daré MBI Inc. Delaware

DARÉ BIOSCIENCE, INC. Up to $19,011,428 Common Stock

Filed Pursuant to Rule 424(b)(5) Registration No. 333-254862 PROSPECTUS SUPPLEMENT (To Prospectus Supplement dated March 31, 2023 and Prospectus Dated April 7, 2021) DARÉ BIOSCIENCE, INC. Up to $19,011,428 Common Stock This prospectus supplement amends and supplements the information in our prospectus supplement dated March 31, 2023, or the Initial Prospectus Supplement. This prospectus supplement

Royalty Interest Financing Agreement entered into as of December 21, 2023 between Dare Bioscience, Inc. and United in Endeavor, LLC

Exhibit 10.12 ROYALTY INTEREST FINANCING AGREEMENT Dated as of December 21, 2023 between UNITED IN ENDEAVOUR, LLC. and DARÉ BIOSCIENCE, INC. 512258979v.3 Table of Contents Page Article I. DEFINITIONS 1 Section 1.01 Definitions. 1 Article II. PURCHASE AND SALE OF THE PURCHASED INTEREST 11 Section 1.01 Purchase and Sale. 11 Section 1.02 Payments to Investor. 11 Section 1.03 Payments to Company. 12 S

Results of Operations and Financial Condition, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2024 DARÉ BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36395 20-4139823 (State or other jurisdiction of incorporation) (Commission Fi

cience, Inc. Policy on Recovery of Erroneously Awarded Compensation

Exhibit 97 DARÉ BIOSCIENCE, INC. POLICY ON RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION November 17, 20231 1.Overview The Board believes that it is in the best interests of the Company and its stockholders to adopt this Policy to provide for the recovery of certain Incentive-Based Compensation in the event of an Accounting Restatement. This Policy is designed to comply with, and shall be interpret

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File No. 001-36395 DARÉ BIOSCIENCE, INC. (Exact

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 23, 2024 DARÉ BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36395 20-4139823 (State or other jurisdiction of incorporation) (Commission

Daré Bioscience Announces Executive Team and Board of Directors Changes

Exhibit 99.1 Daré Bioscience Announces Executive Team and Board of Directors Changes SAN DIEGO, JAN. 26, 2024 — Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced changes in company management which includes the retirement of Chief Financial Officer, Lisa Walters-Hoffert, and the resignation of Chief Commercial Officer, John Fair. Both Ms. Walters-Hoffer

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 17, 2024 DARÉ BIOSCIENCE,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 17, 2024 DARÉ BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36395 20-4139823 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024 DARÉ BIOSCIENCE,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024 DARÉ BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36395 20-4139823 (State or other jurisdiction of incorporation) (Commission F

Corporate presentation, dated January 8, 2024

Exhibit 99.1

Daré Bioscience Secures $12 million in Royalty-backed Investment Structure

Exhibit 99.1 Daré Bioscience Secures $12 million in Royalty-backed Investment Structure $5 million at closing and up to $7 million of additional committed funding SAN DIEGO, December, 26, 2023 – Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced it has entered into a royalty-backed financing agreement that provides Daré with $5 million at closing and up to

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 21, 2023 DARÉ BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36395 20-4139823 (State or other jurisdiction of incorporation) (Commission

Daré Bioscience Announces Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the DARE-PDM1 Phase 1 Clinical Study

Exhibit 99.1 Daré Bioscience Announces Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the DARE-PDM1 Phase 1 Clinical Study Data Support Continued Clinical Development of DARE-PDM1 and its Potential as a First-in-Category Treatment for Primary Dysmenorrhea SAN DIEGO, December 20, 2023 (GLOBE NEWSWIRE) — Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innov

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2023 DARÉ BIOSCIENCE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2023 DARÉ BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36395 20-4139823 (State or other jurisdiction of incorporation) (Commission

Results of Operations and Financial Condition, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2023 DARÉ BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36395 20-4139823 (State or other jurisdiction of incorporation) (Commission

Daré Bioscience, Inc. Performance Bonus Plan, as amended

Exhibit 10.3 DARÉ BIOSCIENCE, INC. PERFORMANCE BONUS PLAN 1.Purpose This Performance Bonus Plan (this “Plan”) is intended to provide an incentive for superior work and to motivate eligible employees of Daré Bioscience, Inc. (the “Company”) and its subsidiaries toward even higher achievement and business results, to tie their goals and interests to those of the Company and its stockholders, and to

Daré Bioscience, Inc. and Subsidiaries Consolidated Statements of Operations and Comprehensive Loss

Exhibit 99.1 Daré Bioscience Reports Third Quarter 2023 Financial Results and Provides Company Update Conference Call and Webcast Today at 4:30 p.m. ET What to Expect for the Remainder of 2023 ● XACIATO™: receipt of $1.8 million triggered by achievement of first commercial milestone under license agreement with Organon ● Ovaprene®: commencement of pivotal Phase 3 contraceptive efficacy study ● Sil

Letter from Mayer Hoffman McCann P.C. dated November 9, 2023

Exhibit 16.1 November 9, 2023 Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 Commissioners: We have read Item 4.01 of Daré Bioscience, Inc.’s Form 8-K dated November 9, 2023, and we agree with the statements set forth in Item 4.01, insofar as they relate to our firm. We have no basis to agree or disagree with other statements of the registrant contained therein. Very t

Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2023 DARÉ BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36395 20-4139823 (State or other jurisdiction of incorporation) (Commission

First Amendment to License Agreement by and between Organon International GmbH and Dare Bioscience, Inc. entered into as of July 4, 2023

Exhibit 10.2 CERTAIN INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. IN THIS EXHIBIT, “[***]” INDICATES WHERE SUCH INFORMATION HAS BEEN OMITTED. FIRST AMENDMENT TO LICENSE AGREEMENT by and between ORGANON INTERNATIONAL GMBH and DARÉ BIOSCIENCE, INC. FIRST AMENDMENT TO LICENSE AGREEMENT This First

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36395 DARÉ BIOSCIENCE, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2023 DARÉ BIOSCIENCE,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2023 DARÉ BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36395 20-4139823 (State or other jurisdiction of incorporation) (Commission

Daré Bioscience Announces Additional Positive Data from Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women and Proposed Endpoints and Patient Population for Phase 3 Program Additional Analyses of Phase 2b Data Conducted in Population of Study

Exhibit 99.1 Daré Bioscience Announces Additional Positive Data from Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women and Proposed Endpoints and Patient Population for Phase 3 Program Additional Analyses of Phase 2b Data Conducted in Population of Study Participants with Female Sexual Interest/Arousal Disorder (FSIAD), With Primary Complaint of Arousal Dysfunction Achieved Statistical Sig

Daré Bioscience Announces Achievement of First Commercial Milestone Under License Agreement for XACIATO™ (Clindamycin Phosphate) Vaginal Gel, 2%, FDA-Approved Treatment for Bacterial Vaginosis in Females 12 Years or Older Daré to receive $1.8 million

Exhibit 99.1 Daré Bioscience Announces Achievement of First Commercial Milestone Under License Agreement for XACIATO™ (Clindamycin Phosphate) Vaginal Gel, 2%, FDA-Approved Treatment for Bacterial Vaginosis in Females 12 Years or Older Daré to receive $1.8 million payment; eligible for additional potential milestone payments of up to $180 million and tiered double-digit royalties based on net sales

Corporate presentation, dated October 16, 2023

Exhibit 99.2

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 12, 2023 DARÉ BIOSCIENCE,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 12, 2023 DARÉ BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36395 20-4139823 (State or other jurisdiction of incorporation) (Commission

Corporate presentation, dated September 11, 2023

Exhibit 99.1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 11, 2023 DARÉ BIOSCIENC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 11, 2023 DARÉ BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36395 20-4139823 (State or other jurisdiction of incorporation) (Commissio

Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 29, 2023 DARÉ BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36395 20-4139823 (State or other jurisdiction of incorporation) (Commission F

Form of Securities Purchase Agreement dated as of August 29, 2023, between Dare Bioscience, Inc. and each purchaser identified on the signature pages thereto

Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of August 29, 2023, between Daré Bioscience, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions

DARÉ BIOSCIENCE, INC. 10,000,000 Shares of Common Stock 10,000,000 Warrants to Purchase up to 10,000,000 Shares of Common Stock Up to 10,000,000 Shares of Common Stock Underlying 10,000,000 Warrants

Filed Pursuant to Rule 424(b)(5) Registration No. 333-254862 PROSPECTUS SUPPLEMENT (To prospectus dated April 7, 2021) DARÉ BIOSCIENCE, INC. 10,000,000 Shares of Common Stock 10,000,000 Warrants to Purchase up to 10,000,000 Shares of Common Stock Up to 10,000,000 Shares of Common Stock Underlying 10,000,000 Warrants We are offering 10,000,000 shares of our common stock and accompanying warrants to

Form of common stock purchase warrants issued on September 1, 2023

Exhibit 4.1 COMMON STOCK PURCHASE WARRANT DARÉ BIOSCIENCE, INC. Warrant Shares: Initial Exercise Date: March 1, 2024 Issue Date: September 1, 2023 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after

Daré Bioscience Announces $7.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

Exhibit 99.1 Daré Bioscience Announces $7.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules SAN DIEGO August 30, 2023 (GLOBE NEWSWIRE) — Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it has entered into a definitive agreement with an institutional investor and an investor affiliated with the licensor of one of the compa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2023 DARÉ BIOSCIENCE,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2023 DARÉ BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36395 20-4139823 (State or other jurisdiction of incorporation) (Commission F

Daré Bioscience, Inc. and Subsidiaries Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)

Exhibit 99.1 Daré Bioscience Reports Second Quarter 2023 Financial Results and Provides a Company Update Conference Call and Webcast Today at 4:30 p.m. ET Second Half 2023 Anticipated Milestones (target indication(s)): ● XACIATO™ First Commercial Sale ● Ovaprene® (hormone-free monthly contraception) – Pivotal Phase 3 Contraceptive Efficacy Study – Patient Enrollment to Begin 4Q2023 ● Sildenafil Cr

Third Amended and Restated Bylaws

THIRD AMENDED AND RESTATED BY-LAWS OF DARÉ BIOSCIENCE, INC. (as amended through January 24, 2023) TABLE OF CONTENTS ARTICLE I STOCKHOLDERS 1 1.1 Place of Meetings 1 1.2 Annual Meeting 1 1.3 Special Meetings 1 1.4 Notice of Meetings 1 1.5 Voting List 2 1.6 Quorum 2 1.7 Adjournments 2 1.8 Voting and Proxies 3 1.9 Action at Meeting 3 1.10 Nomination of Directors 4 1.11 Additional Requirements for Val

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36395 DARÉ BIOSCIENCE, INC.

Letter from Mayer Hoffman McCann P.C. dated August 10, 2023

Exhibit 16.1 August 10, 2023 Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 Commissioners: We have read Item 4.01 of Daré Bioscience, Inc.’s Form 8-K dated August 10, 2023, and we agree with the statements set forth in Item 4.01, insofar as they relate to our firm. We have no basis to agree or disagree with other statements of the registrant contained therein. Very tru

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 19, 2023 DARÉ BIOSCIENCE, IN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 19, 2023 DARÉ BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36395 20-4139823 (State or other jurisdiction of incorporation) (Commission Fil

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 4, 2023 DARÉ BIOSCIENCE, INC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 4, 2023 DARÉ BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36395 20-4139823 (State or other jurisdiction of incorporation) (Commission File

Daré Bioscience Provides Update on Activities to Support Commercial Launch of XACIATO™ (clindamycin phosphate) vaginal gel, 2%, FDA-Approved Treatment for Females 12 and Older with Bacterial Vaginosis Daré to receive $1 million in July 2023 and $181.

Exhibit 99.1 Daré Bioscience Provides Update on Activities to Support Commercial Launch of XACIATO™ (clindamycin phosphate) vaginal gel, 2%, FDA-Approved Treatment for Females 12 and Older with Bacterial Vaginosis Daré to receive $1 million in July 2023 and $181.8 million in potential milestone payments from Organon under XACIATO global license agreement SAN DIEGO, July 5, 2023 (GLOBE NEWSWIRE) —

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2023 DARÉ BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36395 20-4139823 (State or other jurisdiction of incorporation) (Commission Fil

Daré Bioscience Announces Positive Topline Data from the Exploratory Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder Sildenafil Cream-treated patients showed meaningful improvement in the co-primary endpo

EX-99.1 2 ex99-1.htm Exhibit 99.1 Daré Bioscience Announces Positive Topline Data from the Exploratory Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder Sildenafil Cream-treated patients showed meaningful improvement in the co-primary endpoint assessment that evaluated change from baseline in the Arousal-Sensation Domain of the Sexual Function Questionna

Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2023 DARÉ BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36395 20-4139823 (State or other jurisdiction of incorporation) (Commission File

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36395 DARÉ BIOSCIENCE, INC.

Results of Operations and Financial Condition, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 DARÉ BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36395 20-4139823 (State or other jurisdiction of incorporation) (Commission File

Daré Bioscience, Inc. and Subsidiaries Consolidated Statements of Operations and Comprehensive Loss

Exhibit 99.1 Daré Bioscience Reports First Quarter 2023 Financial Results and Provides a Company Update Conference Call and Webcast Today at 4:30 p.m. ET 2023 Anticipated Milestones: ● Sildenafil Cream, 3.6% for Female Sexual Arousal Disorder Phase 2b Clinical Study Topline Data ● XACIATO™ First Commercial Sale ● Ovaprene Pivotal Contraceptive Efficacy Study Initiation ● DARE-PDM1 Phase 1 Clinical

Subsidiaries of the registrant

Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT Name Jurisdiction of Organization Daré Bioscience Operations, Inc. Delaware Daré Bioscience Australia Pty Ltd Australia Pear Tree Pharmaceuticals, Inc. Delaware Daré MBI Inc. Delaware

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File No. 001-36395 DARÉ BIOSCIENCE, INC. (Exact

Amendment No. 3 to the Amended and Restated Exclusive License Agreement, effective as of February 13, 2017, by and among Fred Mermelstein, Ph.D., and Janet Chollet, M.D., Pear Tree Pharmaceuticals, Inc. and Bernadette Klamerus

EX-10.6 2 dare-20221231xex106d.htm EX-10.6 Exhibit 10.6(d) CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. [***] INDICATES THAT INFORMATION HAS BEEN OMITTED. AMENDMENT NO. 3 TO THE AMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENT This Amendment No. 3 to the Amended and Restated

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2023 DARÉ BIOSCIENCE, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2023 DARÉ BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36395 20-4139823 (State or other jurisdiction of incorporation) (Commission Fi

DARÉ BIOSCIENCE, INC. Up to $50,000,000 Common Stock

Filed Pursuant to Rule 424(b)(5) Registration No. 333-254862 PROSPECTUS SUPPLEMENT (To Prospectus dated April 7, 2021) DARÉ BIOSCIENCE, INC. Up to $50,000,000 Common Stock We have entered into a sales agreement, or the Sales Agreement, with Stifel, Nicolaus & Company, Incorporated, or Stifel, and Cantor Fitzgerald & Co., or Cantor, relating to the issuance and sale of shares of our common stock, $

Sales Agreement, dated as of March 31, 2023, between Stifel, Nicolaus & Company, Incorporated, Cantor Fitzgerald & Co. and Daré Bioscience, Inc.

Exhibit 1.1 DARÉ BIOSCIENCE, INC. Shares of Common Stock ($0.0001 par value per share) SALES AGREEMENT March 31, 2023 STIFEL, NICOLAUS & COMPANY, INCORPORATED One South Street, 15th Floor Baltimore, Maryland 21202 CANTOR FITZGERALD & CO. 499 Park Avenue, 4th Floor New York, New York 10022 Ladies and Gentlemen: Daré Bioscience, Inc., a Delaware corporation (the “Company”), confirms its agreement (t

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File No. 001-36395 DARÉ BIOSCIENCE, INC. (Exact

Dare Bioscience, Inc. and Subsidiaries Consolidated Statement of Operations and Comprehensive Loss

Exhibit 99.1 Daré Bioscience Reports Full Year 2022 Financial Results and Provides a Company Update Conference Call and Webcast Today at 4:30 p.m. ET 2022 Daré Key Portfolio Accomplishments: License Agreement with Organon to Commercialize XACIATOTM Ovaprene® IDE Approval for Pivotal Contraceptive Efficacy Study Positive Phase 1/2 Data for both DARE-HRT1 and DARE-VVA1 Three Additional Portfolio Pro

Subsidiaries of the registrant

Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT Name Jurisdiction of Organization Daré Bioscience Operations, Inc. Delaware Daré Bioscience Australia Pty Ltd Australia Pear Tree Pharmaceuticals, Inc. Delaware Daré MBI Inc. Delaware

Amendment No. 3 to the Amended and Restated Exclusive License Agreement, effective as of February 13, 2017, by and among Fred Mermelstein, Ph.D., and Janet Chollet, M.D., Pear Tree Pharmaceuticals, Inc. and Bernadette Klamerus

Exhibit 10.6(d) CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. [***] INDICATES THAT INFORMATION HAS BEEN OMITTED. AMENDMENT NO. 3 TO THE AMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENT This Amendment No. 3 to the Amended and Restated Exclusive License Agreement is entered int

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2023 DARÉ BIOSCIENCE, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2023 DARÉ BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36395 20-4139823 (State or other jurisdiction of incorporation) (Commission Fi

Corporate presentation, dated March 13, 2023

Exhibit 99.1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2023 DARÉ BIOSCIENCE, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2023 DARÉ BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36395 20-4139823 (State or other jurisdiction of incorporation) (Commission Fi

Corporate presentation, dated February 6, 2023

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2023 DARÉ BIOSCIENCE,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2023 DARÉ BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36395 20-4139823 (State or other jurisdiction of incorporation) (Commission

Third Amended and Restated By-laws

Exhibit 3.1 THIRD AMENDED AND RESTATED BY-LAWS OF DARÉ BIOSCIENCE, INC. (as amended through January 24, 2023) TABLE OF CONTENTS ARTICLE I STOCKHOLDERS 1 1.1 Place of Meetings 1 1.2 Annual Meeting 1 1.3 Special Meetings 1 1.4 Notice of Meetings 1 1.5 Voting List 2 1.6 Quorum 2 1.7 Adjournments 2 1.8 Voting and Proxies 2 1.9 Action at Meeting 3 1.10 Nomination of Directors 3 1.11 Additional Requirem

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 24, 2023 DARÉ BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36395 20-4139823 (State or other jurisdiction of incorporation) (Commission

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 24, 2023 DARÉ BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36395 20-4139823 (State or other jurisdiction of incorporation) (Commission

Daré Bioscience Announces Positive Pharmacokinetic (PK) Results from the DARE-HRT1 Phase 1 / 2 Study that Support the Potential of DARE-HRT1 as an Effective Hormone Therapy for both Vasomotor and Vaginal Symptoms of Menopause Daré Plans to Advance DA

EX-99.1 2 ex99-1.htm Exhibit 99.1 Daré Bioscience Announces Positive Pharmacokinetic (PK) Results from the DARE-HRT1 Phase 1 / 2 Study that Support the Potential of DARE-HRT1 as an Effective Hormone Therapy for both Vasomotor and Vaginal Symptoms of Menopause Daré Plans to Advance DARE-HRT1 into Single Phase 3 Efficacy Trial for Treatment of Vasomotor Symptoms (VMS) due to Menopause DARE-HRT1 has

Corporate presentation, dated January 9, 2023

Exhibit 99.2

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 DARÉ BIOSCIENCE,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 DARÉ BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36395 20-4139823 (State or other jurisdiction of incorporation) (Commission F

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2022 DAR? BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36395 20-4139823 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2022 DARÉ BIOSCIENCE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2022 DARÉ BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36395 20-4139823 (State or other jurisdiction of incorporation) (Commission

Daré Bioscience Announces New Development Program, DARE-PDM1, as a Potential First-in-Category Treatment for Primary Dysmenorrhea DARE-PDM1 Utilizes Proprietary Hydrogel Technology for Vaginal Delivery of Diclofenac, a Nonsteroidal Anti-Inflammatory;

Exhibit 99.1 Daré Bioscience Announces New Development Program, DARE-PDM1, as a Potential First-in-Category Treatment for Primary Dysmenorrhea DARE-PDM1 Utilizes Proprietary Hydrogel Technology for Vaginal Delivery of Diclofenac, a Nonsteroidal Anti-Inflammatory; Phase 1 Study Targeted for 2023 2022 Daré Portfolio Accomplishments Include: Two Additional Portfolio Programs (DARE-GML and grant-funde

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2022 DARÉ BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36395 20-4139823 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2022 DARÉ BIOSCIENCE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2022 DARÉ BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36395 20-4139823 (State or other jurisdiction of incorporation) (Commission

Daré Bioscience Announces Positive Topline Results from DARE-VVA1 Phase 1/2 Clinical Study DARE-VVA1 Demonstrated Improvement in Vaginal Cytology Parameters and Bothersome Symptoms of Vulvar and Vaginal Atrophy (VVA), Supporting Ongoing Development I

Exhibit 99.1 Daré Bioscience Announces Positive Topline Results from DARE-VVA1 Phase 1/2 Clinical Study DARE-VVA1 Demonstrated Improvement in Vaginal Cytology Parameters and Bothersome Symptoms of Vulvar and Vaginal Atrophy (VVA), Supporting Ongoing Development Investigational Therapy for Women with VVA Who Cannot, or Should Not, Take Supplemental Estrogen, Including Women with Hormone Receptor-Po

Daré Bioscience Reports Third Quarter 2022 Financial Results and Provides a Company Update Š September 30, 2022: $40.4 million in cash and cash equivalents Š Ovaprene®: IDE approval from FDA for pivotal Phase 3 study; additional study design consider

Dar? Bioscience Reports Third Quarter 2022 Financial Results and Provides a Company Update ? September 30, 2022: $40.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 DAR? BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36395 20-4139823 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36395 DARÉ BIOSCIENCE, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2022 DARÉ BIOSCIENCE,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2022 DARÉ BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36395 20-4139823 (State or other jurisdiction of incorporation) (Commission

Corporate presentation, dated November 3, 2022

Corporate presentation, dated October 17, 2022

Daré Bioscience Announces Positive Efficacy Results from the DARE-HRT1 Phase 1 / 2 Study Statistically Significant Results for Improvement in both the Vasomotor and the Vaginal Symptoms of Menopause DARE-HRT1 has the potential to be the first FDA-app

Exhibit 99.1 Daré Bioscience Announces Positive Efficacy Results from the DARE-HRT1 Phase 1 / 2 Study Statistically Significant Results for Improvement in both the Vasomotor and the Vaginal Symptoms of Menopause DARE-HRT1 has the potential to be the first FDA-approved monthly intravaginal ring delivering both estrogen and progestogen hormone therapy SAN DIEGO, October 17, 2022 (GLOBE NEWSWIRE) — D

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 17, 2022 DARÉ BIOSCIENCE,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 17, 2022 DARÉ BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36395 20-4139823 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 10, 2022 DARÉ BIOSCIENCE,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 10, 2022 DARÉ BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36395 20-4139823 (State or other jurisdiction of incorporation) (Commission

Daré Bioscience Announces IDE Approval for a Single Arm, Open-Label Pivotal Contraceptive Efficacy Study of Ovaprene®, an Investigational Hormone-Free Monthly Intravaginal Contraceptive Ovaprene has the Potential to be the First FDA-Approved Monthly,

Exhibit 99.1 Daré Bioscience Announces IDE Approval for a Single Arm, Open-Label Pivotal Contraceptive Efficacy Study of Ovaprene®, an Investigational Hormone-Free Monthly Intravaginal Contraceptive Ovaprene has the Potential to be the First FDA-Approved Monthly, Self-Administered, Hormone-Free Contraceptive Product SAN DIEGO, October 10, 2022 (GLOBE NEWSWIRE) - Daré Bioscience, Inc. (NASDAQ: DARE

1 DARÉ IN ITALIAN, IT MEANS “TO GIVE.” IN ENGLISH, IT MEANS “TO BE BOLD.” Daré Bioscience NASDAQ: DARE www.darebioscience.com Corporate Presentation: September 12, 2022 ©2022 Daré Bioscience | All rights reserved EXHIBIT 99.1 Forward-Looking Statemen

1 DAR? IN ITALIAN, IT MEANS ?TO GIVE.? IN ENGLISH, IT MEANS ?TO BE BOLD.? Dar? Bioscience NASDAQ: DARE www.darebioscience.com Corporate Presentation: September 12, 2022 ?2022 Dar? Bioscience | All rights reserved EXHIBIT 99.1 Forward-Looking Statements; Disclaimers 2 This presentation is for informational purposes only and is not an offer to sell or a solicitation of an offer to buy any securities

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 12, 2022 DAR? BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36395 20-4139823 (State or other jurisdiction of incorporation) (Commissio

Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 29, 2022 DAR? BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36395 20-4139823 (State or other jurisdiction of incorporation) (Commission F

Daré Bioscience Announces Interim Analysis of Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder Study Enrollment Expected to Complete in 4Q-2022 with Approximately 150 Subjects Topline Data of Phase 2b RESP

Exhibit 99.1 Dar? Bioscience Announces Interim Analysis of Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder Study Enrollment Expected to Complete in 4Q-2022 with Approximately 150 Subjects Topline Data of Phase 2b RESPOND Study Targeted for 2Q-2023 If clinical development is successful, Sildenafil Cream, 3.6% has the potential to be the first FDA-approv

Filing Fee Table

Exhibit 107.1 Calculation of Filing Fee Table Form S-8 (Form Type) Dar? Bioscience, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security type Security class title Fee calculation rule Amount registered (1) Proposed maximum offering price per unit (2) Maximum aggregate offering price Fee rate Amount of registration fee Equity Common Stock, $0.000

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36395 DAR? BIOSCIENCE, INC.

Restated Certificate of Incorporation, as amended to date

Exhibit 3.1 State of Delaware Secretary of State Division of Corporations Delivered 01:12 PM 07/14/2022 FILED 01:12 PM 07/14/22 SR 20222989692 ? File Number 4067151 CERTIFICATE OF AMENDMENT OF RESTATED CERTIFICATE OF INCORPORATION OF DAR? BIOSCIENCE, INC. Dar? Bioscience, Inc. (the ?Corporation?), a corporation organized and existing under the General Corporation Law of the State of Delaware (the

As filed with the Securities and Exchange Commission on August 09, 2022

As filed with the Securities and Exchange Commission on August 09, 2022 Registration No.

Daré Bioscience Reports Second Quarter 2022 Financial Results and Provides a Company Update

Exhibit 99.1 Daré Bioscience Reports Second Quarter 2022 Financial Results and Provides a Company Update ● June 30, 2022: $32.1 million in cash and cash equivalents ● July 2022: approximately $18.0 million in cash received subsequent to quarter-end: ○ $10.0 million upfront license fee under global license agreement with Organon to commercialize XACIATOTM (clindamycin phosphate) vaginal gel, 2%, an

Results of Operations and Financial Condition, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2022 DAR? BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36395 20-4139823 (State or other jurisdiction of incorporation) (Commission Fi

Corporate presentation dated July 25, 2022

Exhibit 99.1

Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 25, 2022 DARÉ BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36395 20-4139823 (State or other jurisdiction of incorporation) (Commission Fil

Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2022 DAR? BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36395 20-4139823 (State or other jurisdiction of incorporation) (Commission F

Certificate of Amendment of Restated Certificate of Incorporation dated July 14, 2022

Exhibit 3.1 CERTIFICATE OF AMENDMENT OF RESTATED CERTIFICATE OF INCORPORATION OF DAR? BIOSCIENCE, INC. Dar? Bioscience, Inc. (the ?Corporation?), a corporation organized and existing under the General Corporation Law of the State of Delaware (the ?DGCL?), hereby certifies as follows: 1. This Certificate of Amendment (this ?Certificate of Amendment?) amends the provisions of the Corporation?s Resta

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 7, 2022 DAR? BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36395 20-4139823 (State or other jurisdiction of incorporation) (Commission File

Regulation FD Disclosure, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2022 DAR? BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36395 20-4139823 (State or other jurisdiction of incorporation) (Commission Fil

Daré Bioscience Announces Closing of Global License Agreement with Organon to Commercialize XACIATO™ (clindamycin phosphate vaginal gel, 2%), FDA-Approved Treatment for Females 12 and Older with Bacterial Vaginosis

Exhibit 99.1 Daré Bioscience Announces Closing of Global License Agreement with Organon to Commercialize XACIATO™ (clindamycin phosphate vaginal gel, 2%), FDA-Approved Treatment for Females 12 and Older with Bacterial Vaginosis Daré will receive a $10 million upfront payment from Organon An estimated 21 million American women experience bacterial vaginosis SAN DIEGO, June 30, 2022 (GLOBE NEWSWIRE)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive

Form of Incentive Stock Option Agreement for grants under the Daré Bioscience, Inc. 2022 Stock Incentive Plan

Exhibit 10.1(b) Dar? Bioscience, Inc. Incentive Stock Option Agreement Granted under the Dar? Bioscience, Inc. 2022 Stock Incentive Plan 1. Grant of Option. This agreement evidences the grant by Dar? Bioscience, Inc., a Delaware corporation (the ?Company?), on ###GRANTDATE### (the ?Grant Date?) to ###PARTICIPANTNAME### (the ?Participant?), of an Option to purchase, in whole or in part, on the term

Daré Bioscience Announces Partial Adjournment of Annual Meeting of Stockholders to July 14, 2022 Meeting to be reconvened solely with respect to Proposal 5

Exhibit 99.1 Daré Bioscience Announces Partial Adjournment of Annual Meeting of Stockholders to July 14, 2022 Meeting to be reconvened solely with respect to Proposal 5 SAN DIEGO, June 24, 2022 (GLOBE NEWSWIRE) – Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced partial adjournment of its 2022 Annual Meeting of Stockholders (the “Annual Meeting”) and voti

Daré Bioscience, Inc. 2022 Stock Incentive Plan

Exhibit 10.1(a) DARÉ BIOSCIENCE, INC. 2022 STOCK INCENTIVE PLAN Adopted by the Board of Directors: April 11, 2022 Approved by the Shareholders: June 23, 2022 1. Purpose The purpose of this 2022 Stock Incentive Plan (the “Plan”) of Daré Bioscience, Inc., a Delaware corporation (the “Company”), is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract, r

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive

Regulation FD Disclosure, Submission of Matters to a Vote of Security Holders, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2022 DAR? BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36395 20-4139823 (State or other jurisdiction of incorporation) (Commission Fil

Form of Nonstatutory Stock Option Agreement for grants under the Daré Bioscience, Inc. 2022 Stock Incentive Plan

Exhibit 10.1(c) Dar? Bioscience, Inc. Nonstatutory Stock Option Agreement Granted under the Dar? Bioscience, Inc. 2022 Stock Incentive Plan 1. Grant of Option. This agreement evidences the grant by Dar? Bioscience, Inc., a Delaware corporation (the ?Company?), on ###GRANTDATE### (the ?Grant Date?) to ###PARTICIPANTNAME### (the ?Participant?), of an Option to purchase, in whole or in part, on the t

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive

Daré Bioscience DARÉ IN ITALIAN, IT MEANS “TO GIVE.” IN ENGLISH, IT MEANS “TO BE BOLD.” NASDAQ: DARE www.darebioscience.com Corporate Presentation: May 23, 2022 ©2022 Daré Bioscience | All rights reserved Exhibit 99.1 Forward-Looking Statements; Disc

Dar? Bioscience DAR? IN ITALIAN, IT MEANS ?TO GIVE.? IN ENGLISH, IT MEANS ?TO BE BOLD.? NASDAQ: DARE www.darebioscience.com Corporate Presentation: May 23, 2022 ?2022 Dar? Bioscience | All rights reserved Exhibit 99.1 Forward-Looking Statements; Disclaimers 2 This presentation is for informational purposes only and is not an offer to sell or a solicitation of an offer to buy any securities of Dar?

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2022 DAR? BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36395 20-4139823 (State or other jurisdiction of incorporation) (Commission File

Daré Bioscience Reports First Quarter 2022 Financial Results and Provides a Company Update • $39.3 million in cash and cash equivalents at March 31, 2022 • Announced initiation of DARE-HRT1 Phase 1/2 clinical study in April 2022 • Organon exclusive g

Dar? Bioscience Reports First Quarter 2022 Financial Results and Provides a Company Update ? $39.

Amended and Restated Non-Employee Director Compensation Policy (as amended through January 2022)

Exhibit 10.2 DAR? BIOSCIENCE, INC. AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY1 The board of directors (the ?Board?) of Dar? Bioscience, Inc. (the ?Company?) has approved this amended and restated non-employee director compensation policy (this ?Policy?). Cash Compensation Under this Policy, the Company will pay its non-employee directors retainers in cash, unless a director ele

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2022 DAR? BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36395 20-4139823 (State or other jurisdiction of incorporation) (Commission File

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36395 DAR? BIOSCIENCE, INC.

Consent, Waiver and Stand-By License Agreement, dated March 30, 2022, by and among TriLogic Pharma, LLC, and MilanaPharm LLC, Dare Bioscience, Inc., and Organon International GmbH.

Exhibit 10.2 CERTAIN INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. IN THIS EXHIBIT, ?[***]? INDICATES WHERE SUCH INFORMATION HAS BEEN OMITTED. CONSENT, WAIVER AND STAND-BY LICENSE AGREEMENT This CONSENT, WAIVER AND STAND-BY LICENSE AGREEMENT (this ?Agreement?), dated March 30, 2022 (?Execution D

Exclusive License Agreement dated March 31, 2022 between Organon International GmbH and Dare Bioscience, Inc., effective as of June 30, 2022

Exhibit 10.1 CERTAIN INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. IN THIS EXHIBIT, ?[***]? INDICATES WHERE SUCH INFORMATION HAS BEEN OMITTED. EXCLUSIVE LICENSE AGREEMENT by and between ORGANON INTERNATIONAL GMBH and DAR? BIOSCIENCE, INC. NAI-1530421791v2 EXCLUSIVE LICENSE AGREEMENT This Exclusi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State

Exhibit 99.1 News Release _________________________________________________________________________________ Organon Media Contacts: Karissa Peer Organon Investor Contacts: Jennifer Halchak (614) 314-8094 Kate Vossen (732) 675-8448 (201) 275-2711 Edwa

Exhibit 99.1 News Release Organon Media Contacts: Karissa Peer Organon Investor Contacts: Jennifer Halchak (614) 314-8094 Kate Vossen (732) 675-8448 (201) 275-2711 Edward Barger (267) 614-4669 Dar? Media Contacts: Jake Robison (619) 849-5383 Dar? Investor Contacts: Lee Roth (212) 213-0006 Organon Enters into Global License Agreement to Commercialize Dar? Bioscience?s XACIATO? (clindamycin phosphat

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2022 DAR? BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36395 20-4139823 (State or other jurisdiction of incorporation) (Commission Fi

Subsidiaries of the registrant

Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT Name Jurisdiction of Organization Dar? Bioscience Operations, Inc. Delaware Dar? Bioscience Australia Pty Ltd Australia Pear Tree Pharmaceuticals, Inc. Delaware Dar? MBI Inc. Delaware

As filed with the Securities and Exchange Commission on March 31, 2022

As filed with the Securities and Exchange Commission on March 31, 2022 Registration No.

Warrant Agreement to purchase shares of common stock of the registrant with Aquilo Partners, L.P., entered into as of October 16, 2016.

EX-4.2 2 ex4210kx2021.htm EX-4.2 Exhibit 4.2 EXECUTION COPY THIS WARRANT AND THE SHARES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), OR ANY STATE SECURITIES LAWS, AND MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR, SUBJECT TO SECTION 1

Daré Bioscience Reports Full-Year 2021 Financial Results and Provides a Company Update Entered into exclusive global license agreement with Organon to commercialize XACIATOTM (clindamycin phosphate vaginal gel, 2%) that includes a $10 million upfront

Dar? Bioscience Reports Full-Year 2021 Financial Results and Provides a Company Update Entered into exclusive global license agreement with Organon to commercialize XACIATOTM (clindamycin phosphate vaginal gel, 2%) that includes a $10 million upfront cash payment once effective U.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File No. 001-36395 DAR? BIOSCIENCE, INC. (Exact

Filing Fee Table

Exhibit 107.1 Calculation of Filing Fee Table Form S-8 (Form Type) Dar? Bioscience, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security type Security class title Fee calculation rule Amount registered (1) Proposed maximum offering price per unit (2) Maximum aggregate offering price Fee rate Amount of registration fee Equity Common Stock, $0.000

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2022 DAR? BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36395 20-4139823 (State or other jurisdiction of incorporation) (Commission Fi

Daré Bioscience DARÉ IN ITALIAN, IT MEANS “TO GIVE.” IN ENGLISH, IT MEANS “TO BE BOLD.” NASDAQ: DARE www.darebioscience.com Corporate Presentation: March 7, 2022 ©2022 Daré Bioscience | All rights reserved Exhibit 99.1 Forward-Looking Statements; Dis

EX-99.1 2 ex99103072022.htm EX-99.1 Daré Bioscience DARÉ IN ITALIAN, IT MEANS “TO GIVE.” IN ENGLISH, IT MEANS “TO BE BOLD.” NASDAQ: DARE www.darebioscience.com Corporate Presentation: March 7, 2022 ©2022 Daré Bioscience | All rights reserved Exhibit 99.1 Forward-Looking Statements; Disclaimers 2 This presentation is for informational purposes only and is not an offer to sell or a solicitation of a

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2022 DARÉ BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36395 20-4139823 (State or other jurisdiction of incorporation) (Commission Fil

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2022 DARÉ BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36395 20-4139823 (State or other jurisdiction of incorporation) (Commission

Daré Bioscience DARÉ IN ITALIAN, IT MEANS “TO GIVE.” IN ENGLISH, IT MEANS “TO BE BOLD.” NASDAQ: DARE www.darebioscience.com Corporate Presentation: February 14, 2022 ©2022 Daré Bioscience | All rights reserved Exhibit 99.1 Forward-Looking Statements;

Dar? Bioscience DAR? IN ITALIAN, IT MEANS ?TO GIVE.? IN ENGLISH, IT MEANS ?TO BE BOLD.? NASDAQ: DARE www.darebioscience.com Corporate Presentation: February 14, 2022 ?2022 Dar? Bioscience | All rights reserved Exhibit 99.1 Forward-Looking Statements; Disclaimers 2 This presentation is for informational purposes only and is not an offer to sell or a solicitation of an offer to buy any securities of

DARE / Dare Bioscience Inc / VANGUARD INDEX FUNDS - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Dare Bioscience Inc. Title of Class of Securities: Common Stock CUSIP Number: 23666P101 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

DARE / Dare Bioscience Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Dare Bioscience Inc. Title of Class of Securities: Common Stock CUSIP Number: 23666P101 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2022 DAR? BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36395 20-4139823 (State or other jurisdiction of incorporation) (Commission

Daré Bioscience DARÉ IN ITALIAN, IT MEANS “TO GIVE.” IN ENGLISH, IT MEANS “TO BE BOLD.” NASDAQ: DARE www.darebioscience.com Corporate Presentation: January 10, 2022 ©2022 Daré Bioscience | All rights reserved Exhibit 99.1 Forward-Looking Statements;

ex991011022 Daré Bioscience DARÉ IN ITALIAN, IT MEANS “TO GIVE.” IN ENGLISH, IT MEANS “TO BE BOLD.” NASDAQ: DARE www.darebioscience.com Corporate Presentation: January 10, 2022 ©2022 Daré Bioscience | All rights reserved Exhibit 99.1 Forward-Looking Statements; Disclaimers 2 This presentation is for informational purposes only and is not an offer to sell or a solicitation of an offer to buy any se

Daré Bioscience DARÉ IN ITALIAN, IT MEANS “TO GIVE.” IN ENGLISH, IT MEANS “TO BE BOLD.” NASDAQ: DARE www.darebioscience.com Corporate Presentation: December 8, 2021 ©2021 Daré Bioscience | All rights reserved Exhibit 99.1 Forward-Looking Statements;

Dar? Bioscience DAR? IN ITALIAN, IT MEANS ?TO GIVE.? IN ENGLISH, IT MEANS ?TO BE BOLD.? NASDAQ: DARE www.darebioscience.com Corporate Presentation: December 8, 2021 ?2021 Dar? Bioscience | All rights reserved Exhibit 99.1 Forward-Looking Statements; Disclaimers 2 This presentation is for informational purposes only and is not an offer to sell or a solicitation of an offer to buy any securities of

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 8, 2021 DAR? BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36395 20-4139823 (State or other jurisdiction of incorporation) (Commission

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 7, 2021 DARÉ BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36395 20-4139823 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to DARÉ BIOSCIENCE, INC.

Amendment to License Agreement effective as of September 21, 2021 by and among Daré Bioscience, Inc., TriLogic Pharma, LLC and MilanaPharm LLC

Exhibit 10.1 Second Amendment to License Agreement This Second Amendment to License Agreement (?Amendment?) is effective as of September 21, 2021 (the ?Second Amendment Date?) and is made by and among Dar? Bioscience, Inc., a Delaware corporation (?Dar??), and TriLogic Pharma, LLC, a Delaware limited liability company (?TriLogic?), and MilanaPharm LLC, a Delaware limited liability company (?Milana

Cooperative Research and Development Agreement entered into as of July 8, 2021 between Dare Bioscience, Inc. and the Eunice Kennedy Schriver National Institutes of Child Health and Human Development Institute

Exhibit 10.2 CERTAIN INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. [**] INDICATES THAT INFORMATION HAS BEEN EXCLUDED. Cooperative Research And Development Agreement COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT (CRADA) This Cover Page identifies the Parties to this CRADA: The U.S. Department o

DARÉ BIOSCIENCE, INC. Up to $50,000,000 Common Stock

Filed Pursuant to Rule 424(b)(5) Registration No. 333-254862 PROSPECTUS SUPPLEMENT (To Prospectus dated April 7, 2021) DARÉ BIOSCIENCE, INC. Up to $50,000,000 Common Stock We have entered into a sales agreement, or the Sales Agreement, with SVB Leerink LLC, or SVB Leerink, relating to the issuance and sale of shares of our common stock, $0.0001 par value per share, including up to $50,000,000 of s

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 13, 2021 DAR? BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36395 20-4139823 (State or other jurisdiction of incorporation) (Commission

, 2021, between SVB Leerink LLC

EX-1.1 2 ex11-atmsalesagreement1013.htm EX-1.1 Exhibit 1.1 DARÉ BIOSCIENCE, INC. Shares of Common Stock ($0.0001 par value per share) SALES AGREEMENT October 13, 2021 SVB LEERINK LLC 1301 Avenue of the Americas, 12th Floor New York, New York 10019 Ladies and Gentlemen: Daré Bioscience, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with SVB Leerink LLC (the

Daré Bioscience DARÉ IN ITALIAN, IT MEANS “TO GIVE.” IN ENGLISH, IT MEANS “TO BE BOLD.” NASDAQ: DARE www.darebioscience.com Corporate Presentation: September 30, 2021 ©2021 Daré Bioscience | All rights reserved Exhibit 99.1 Forward-Looking Statements

Dar? Bioscience DAR? IN ITALIAN, IT MEANS ?TO GIVE.? IN ENGLISH, IT MEANS ?TO BE BOLD.? NASDAQ: DARE www.darebioscience.com Corporate Presentation: September 30, 2021 ?2021 Dar? Bioscience | All rights reserved Exhibit 99.1 Forward-Looking Statements; Disclaimers 2 This presentation is for informational purposes only and is not an offer to sell or a solicitation of an offer to buy any securities o

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2021 DARÉ BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36395 20-4139823 (State or other jurisdiction of incorporation) (Commissio

Daré Bioscience DARÉ IN ITALIAN, IT MEANS “TO GIVE.” IN ENGLISH, IT MEANS “TO BE BOLD.” NASDAQ: DARE www.darebioscience.com Corporate Presentation: September 9, 2021 ©2021 Daré Bioscience | All rights reserved Exhibit 99.1 Forward-Looking Statements;

Dar? Bioscience DAR? IN ITALIAN, IT MEANS ?TO GIVE.? IN ENGLISH, IT MEANS ?TO BE BOLD.? NASDAQ: DARE www.darebioscience.com Corporate Presentation: September 9, 2021 ?2021 Dar? Bioscience | All rights reserved Exhibit 99.1 Forward-Looking Statements; Disclaimers 2 This presentation is for informational purposes only and is not an offer to sell or a solicitation of an offer to buy any securities of